Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29569977 | 1.00 | MEN1 (0.44) | MEN1KMT2ATSHRSMN1; SMN2MAPT | |
| SCHEMBL26531201 | 0.92 | MEN1 (0.43) | MEN1KMT2ATSHRSMN1; SMN2MAPT | |
| SCHEMBL26999077 | 0.87 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL23297337 | 0.85 | MAPT (0.53) | MEN1KMT2ATSHRSMN1; SMN2MAPT | |
| SCHEMBL23528330 | 0.81 | GRIN1 (0.45) | MEN1KMT2ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL23528583 | 0.78 | MEN1 (0.46) | MEN1KMT2ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL23528334 | 0.78 | KDM4E (0.46) | MEN1KMT2ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL24035613 | 0.78 | TP53 (0.50) | MEN1KMT2ATSHRSMN1; SMN2MAPT | |
| SCHEMBL23528798 | 0.77 | MAPT (0.47) | MEN1KMT2ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL23528355 | 0.76 | MET (0.46) | MEN1KMT2ATSHRSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012395-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11873290-B2 | — | — | 2024-01-16 | — | — | US | disclosed |
| US-11873290-B2 | — | — | 2024-01-16 | — | — | US | disclosed |
| US-11873290-B2 | — | — | 2024-01-16 | — | — | US | disclosed |
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-4248973-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4248973-A2 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3877376-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3877376-B1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2021231615-A1 | SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-11091464-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-11091464-B2 | Pyridazinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210188814-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-06-24 | — | — | US | disclosed |
| US-20210188814-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188814-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | MEN1 4368/4885KMT2A 4169/4885TSHR 3552/4885 |
| US-20230321091-A1 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, MUSK, SMN1; SMN2 | MEN1 4467/4885KMT2A 3767/4885TSHR 3553/4885 |
| US-12012395-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | MEN1 4368/4885KMT2A 4169/4885TSHR 3552/4885 |
| US-11873290-B2 | — | IL6, MUSK, IL6ST | MEN1 4771/4885KMT2A 4022/4885TSHR 3809/4885 |
| US-11091464-B2 | Pyridazinone compounds and uses thereof | IL6, IL1B, IL1A | MEN1 4368/4885KMT2A 4169/4885TSHR 3552/4885 |
| US-20240025879-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | MEN1 4368/4885KMT2A 4169/4885TSHR 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.